Report cover image

Global Live Vaccines Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 197 Pages
SKU # APRC20557355

Description

Summary

According to APO Research, the global Live Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Live Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Live Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Live Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Live Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Live Vaccines market include Astellas Pharma, Emergent BioSolutions, AstraZeneca, GlaxoSmithKline, Pfizer, Merck and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Live Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Live Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Live Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Live Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Live Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Live Vaccines sales, projected growth trends, production technology, application and end-user industry.

Live Vaccines Segment by Company

Astellas Pharma
Emergent BioSolutions
AstraZeneca
GlaxoSmithKline
Pfizer
Merck
Novartis
Live Vaccines Segment by Type

Monovalent Live Vaccines
Multivalent Live Vaccines
Live Vaccines Segment by Application

Adults
Children
Live Vaccines Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Live Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Live Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Live Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Live Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live Vaccines industry.
Chapter 3: Detailed analysis of Live Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Live Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Live Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Live Vaccines Sales Value (2020-2031)
1.2.2 Global Live Vaccines Sales Volume (2020-2031)
1.2.3 Global Live Vaccines Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Live Vaccines Market Dynamics
2.1 Live Vaccines Industry Trends
2.2 Live Vaccines Industry Drivers
2.3 Live Vaccines Industry Opportunities and Challenges
2.4 Live Vaccines Industry Restraints
3 Live Vaccines Market by Company
3.1 Global Live Vaccines Company Revenue Ranking in 2024
3.2 Global Live Vaccines Revenue by Company (2020-2025)
3.3 Global Live Vaccines Sales Volume by Company (2020-2025)
3.4 Global Live Vaccines Average Price by Company (2020-2025)
3.5 Global Live Vaccines Company Ranking (2023-2025)
3.6 Global Live Vaccines Company Manufacturing Base and Headquarters
3.7 Global Live Vaccines Company Product Type and Application
3.8 Global Live Vaccines Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Live Vaccines Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Live Vaccines Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Live Vaccines Market by Type
4.1 Live Vaccines Type Introduction
4.1.1 Monovalent Live Vaccines
4.1.2 Multivalent Live Vaccines
4.2 Global Live Vaccines Sales Volume by Type
4.2.1 Global Live Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Live Vaccines Sales Volume by Type (2020-2031)
4.2.3 Global Live Vaccines Sales Volume Share by Type (2020-2031)
4.3 Global Live Vaccines Sales Value by Type
4.3.1 Global Live Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Live Vaccines Sales Value by Type (2020-2031)
4.3.3 Global Live Vaccines Sales Value Share by Type (2020-2031)
5 Live Vaccines Market by Application
5.1 Live Vaccines Application Introduction
5.1.1 Adults
5.1.2 Children
5.2 Global Live Vaccines Sales Volume by Application
5.2.1 Global Live Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Live Vaccines Sales Volume by Application (2020-2031)
5.2.3 Global Live Vaccines Sales Volume Share by Application (2020-2031)
5.3 Global Live Vaccines Sales Value by Application
5.3.1 Global Live Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Live Vaccines Sales Value by Application (2020-2031)
5.3.3 Global Live Vaccines Sales Value Share by Application (2020-2031)
6 Live Vaccines Regional Sales and Value Analysis
6.1 Global Live Vaccines Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Live Vaccines Sales by Region (2020-2031)
6.2.1 Global Live Vaccines Sales by Region: 2020-2025
6.2.2 Global Live Vaccines Sales by Region (2026-2031)
6.3 Global Live Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Live Vaccines Sales Value by Region (2020-2031)
6.4.1 Global Live Vaccines Sales Value by Region: 2020-2025
6.4.2 Global Live Vaccines Sales Value by Region (2026-2031)
6.5 Global Live Vaccines Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Live Vaccines Sales Value (2020-2031)
6.6.2 North America Live Vaccines Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Live Vaccines Sales Value (2020-2031)
6.7.2 Europe Live Vaccines Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Live Vaccines Sales Value (2020-2031)
6.8.2 Asia-Pacific Live Vaccines Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Live Vaccines Sales Value (2020-2031)
6.9.2 South America Live Vaccines Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Live Vaccines Sales Value (2020-2031)
6.10.2 Middle East & Africa Live Vaccines Sales Value Share by Country, 2024 VS 2031
7 Live Vaccines Country-level Sales and Value Analysis
7.1 Global Live Vaccines Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Live Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Live Vaccines Sales by Country (2020-2031)
7.3.1 Global Live Vaccines Sales by Country (2020-2025)
7.3.2 Global Live Vaccines Sales by Country (2026-2031)
7.4 Global Live Vaccines Sales Value by Country (2020-2031)
7.4.1 Global Live Vaccines Sales Value by Country (2020-2025)
7.4.2 Global Live Vaccines Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Live Vaccines Sales Value Growth Rate (2020-2031)
7.5.2 USA Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Live Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Canada Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Live Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Live Vaccines Sales Value Growth Rate (2020-2031)
7.8.2 Germany Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Live Vaccines Sales Value Growth Rate (2020-2031)
7.9.2 France Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.9.3 France Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Live Vaccines Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Live Vaccines Sales Value Growth Rate (2020-2031)
7.11.2 Italy Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Live Vaccines Sales Value Growth Rate (2020-2031)
7.12.2 Spain Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Live Vaccines Sales Value Growth Rate (2020-2031)
7.13.2 Russia Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Live Vaccines Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Live Vaccines Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Live Vaccines Sales Value Growth Rate (2020-2031)
7.16.2 China Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.16.3 China Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Live Vaccines Sales Value Growth Rate (2020-2031)
7.17.2 Japan Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Live Vaccines Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Live Vaccines Sales Value Growth Rate (2020-2031)
7.19.2 India Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.19.3 India Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Live Vaccines Sales Value Growth Rate (2020-2031)
7.20.2 Australia Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Live Vaccines Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Live Vaccines Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Live Vaccines Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Live Vaccines Sales Value Growth Rate (2020-2031)
7.24.2 Chile Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Live Vaccines Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Live Vaccines Sales Value Growth Rate (2020-2031)
7.26.2 Peru Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Live Vaccines Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Live Vaccines Sales Value Growth Rate (2020-2031)
7.28.2 Israel Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Live Vaccines Sales Value Growth Rate (2020-2031)
7.29.2 UAE Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Live Vaccines Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Live Vaccines Sales Value Growth Rate (2020-2031)
7.31.2 Iran Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Live Vaccines Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Live Vaccines Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Live Vaccines Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Live Vaccines Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Astellas Pharma
8.1.1 Astellas Pharma Comapny Information
8.1.2 Astellas Pharma Business Overview
8.1.3 Astellas Pharma Live Vaccines Sales, Value and Gross Margin (2020-2025)
8.1.4 Astellas Pharma Live Vaccines Product Portfolio
8.1.5 Astellas Pharma Recent Developments
8.2 Emergent BioSolutions
8.2.1 Emergent BioSolutions Comapny Information
8.2.2 Emergent BioSolutions Business Overview
8.2.3 Emergent BioSolutions Live Vaccines Sales, Value and Gross Margin (2020-2025)
8.2.4 Emergent BioSolutions Live Vaccines Product Portfolio
8.2.5 Emergent BioSolutions Recent Developments
8.3 AstraZeneca
8.3.1 AstraZeneca Comapny Information
8.3.2 AstraZeneca Business Overview
8.3.3 AstraZeneca Live Vaccines Sales, Value and Gross Margin (2020-2025)
8.3.4 AstraZeneca Live Vaccines Product Portfolio
8.3.5 AstraZeneca Recent Developments
8.4 GlaxoSmithKline
8.4.1 GlaxoSmithKline Comapny Information
8.4.2 GlaxoSmithKline Business Overview
8.4.3 GlaxoSmithKline Live Vaccines Sales, Value and Gross Margin (2020-2025)
8.4.4 GlaxoSmithKline Live Vaccines Product Portfolio
8.4.5 GlaxoSmithKline Recent Developments
8.5 Pfizer
8.5.1 Pfizer Comapny Information
8.5.2 Pfizer Business Overview
8.5.3 Pfizer Live Vaccines Sales, Value and Gross Margin (2020-2025)
8.5.4 Pfizer Live Vaccines Product Portfolio
8.5.5 Pfizer Recent Developments
8.6 Merck
8.6.1 Merck Comapny Information
8.6.2 Merck Business Overview
8.6.3 Merck Live Vaccines Sales, Value and Gross Margin (2020-2025)
8.6.4 Merck Live Vaccines Product Portfolio
8.6.5 Merck Recent Developments
8.7 Novartis
8.7.1 Novartis Comapny Information
8.7.2 Novartis Business Overview
8.7.3 Novartis Live Vaccines Sales, Value and Gross Margin (2020-2025)
8.7.4 Novartis Live Vaccines Product Portfolio
8.7.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Live Vaccines Value Chain Analysis
9.1.1 Live Vaccines Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Live Vaccines Sales Mode & Process
9.2 Live Vaccines Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Live Vaccines Distributors
9.2.3 Live Vaccines Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.